Unraveling the complexity of amorphous solid as direct ingredient for conventional oral solid dosage form: The story of Elagolix Sodium.

Autor: Ho R; Small Molecule CMC Development, AbbVie Inc., 1 N Waukegan Road, North Chicago, IL 60064, USA. Electronic address: raimundo.ho@abbvie.com., Hong RS; Small Molecule CMC Development, AbbVie Inc., 1 N Waukegan Road, North Chicago, IL 60064, USA., Kalkowski J; Small Molecule CMC Development, AbbVie Inc., 1 N Waukegan Road, North Chicago, IL 60064, USA., Spence KC; Operations Product Development Science & Technology, AbbVie Inc., 1 N Waukegan Road, North Chicago, IL 60064, USA., Kruger AW; Operations Product Development Science & Technology, AbbVie Inc., 1 N Waukegan Road, North Chicago, IL 60064, USA., Jayanth J; CMC Strategy & Portfolio Leadership, AbbVie Inc., 1 N Waukegan Road, North Chicago, IL 60064, USA., Nere NK; Small Molecule CMC Development, AbbVie Inc., 1 N Waukegan Road, North Chicago, IL 60064, USA., Mukherjee S; Operations Product Development Science & Technology, AbbVie Inc., 1 N Waukegan Road, North Chicago, IL 60064, USA., Sheikh AY; Small Molecule CMC Development, AbbVie Inc., 1 N Waukegan Road, North Chicago, IL 60064, USA., Bordawekar SV; Small Molecule CMC Development, AbbVie Inc., 1 N Waukegan Road, North Chicago, IL 60064, USA.

Publikováno v: International journal of pharmaceutics [Int J Pharm] 2024 Nov 15; Vol. 665, pp. 124656. Date of Electronic Publication: 2024 Sep 06.